Ranking · Winter 2020 · Healthcare · Diagnostics

Isabl

Cancer tests based on whole genome and transcriptome data.

6.9%

odds of being acquired in the next two years

1.0× the average (6.8%)

#1920 of 4,339 active YC companies · top 45%

Team of 5 · New York City, NY, USA; New York, NY, USA; Remote

Raises the odds

↑ based in Fully Remote

↑ team of 3–5

↑ based in United States of America

↑ based in America / Canada

Lowers the odds

↓ industry: Healthcare

↓ tag: Biotech

↓ sector: Diagnostics

From the model: how this company's profile compares with companies that were and weren't acquired since 2024. How it works.

Signals brief

ExitOdds reads Isabl's website and YC profile; Contextrie keeps the passages that bear on an acquisition, and every signal quotes its source.

3 free briefs left today

isabl.io YC profile

Statistical estimate from public directory data as of 2026-10-07; it can't see revenue, funding or talks. Not investment advice. ExitOdds is independent and not affiliated with Y Combinator.

Built with open source on GitHub